Evaluation of efficacy of rose capsule on ulcerative colitis patients

Evaluation of efficacy of rose capsule on ulcerative colitis patients : a randomized double-blind placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200303046677N2

Enrollment

Registered

2020-12-05

Start date

2021-02-18

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis. Ulcerative colitis

Interventions

Intervention 1: Intervention group: Rose capsules. Intervention 2: Control group: placebo.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients 18-65 years old Mild to moderate ulcerative colitis

Exclusion criteria

Exclusion criteria: Pregnancy Breastfeeding Active urinary tract infection History of seizure Concomitant use of a chemical or other herbal medicine associated with symptoms of functional indigestion Any possible severe drug-related side effects History of gastrointestinal ulcer or reflux disease Taking anticoagulants Irritable bowel syndrome Surgery in the esophagus and stomach and intestines Serious organ diseases such as diabetes and cardiovascular disease Consumption of any type of drug Severe mental retardation The patient's unwillingness to continue the project Failure to complete the consent form Warning symptoms (severe weight loss, anemia, blood in the stool, dysphagia)

Design outcomes

Primary

Measure	Time frame
Rectal Bleeding. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;Fecal incontinence. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;Abdominal pain and cramps. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;General situation. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;Pain when touching the abdomen. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;Need anti-diarrheal drug. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;Diarrhea. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;Nocturnal diarrhea. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.	—

Measure

Time frame

Rectal Bleeding. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;Fecal incontinence. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;Abdominal pain and cramps. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;General situation. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;Pain when touching the abdomen. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;Need anti-diarrheal drug. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;Diarrhea. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.;Nocturnal diarrhea. Timepoint: At the beginning and end of the second and fourth week. Method of measurement: questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRasool Choopani

Shahid Beheshti University of Medical Sciences

rchoopani@sbmu.ac.ir+98 21 8877 3521

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026